Lanean...
Contraindications to intravenous rtPA for acute stroke: A critical reappraisal
Only 1%–5% of patients with acute ischemic stroke presenting within 3 hours of symptoms receive IV recombinant tissue plasminogen activator (rtPA)—the only effective treatment available. The administration of rtPA is limited by extensive exclusion criteria, many of which are not based on evidence, b...
Gorde:
| Argitaratua izan da: | Neurol Clin Pract |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Academy of Neurology
2013
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5798502/ https://ncbi.nlm.nih.gov/pubmed/29473642 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0b013e318296f0a9 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|